BriaCell Therapeutics Corp. Warrant
BCTXZHealthcare|Biotechnology|CA
$0.11
-0.04 (-24.30%)
DCF Value
$1.39
Tangible Book / Share
$1.77
Cash / Share
$2.36
Financials
Financial Snapshot
Market Cap
$212.5K
Enterprise Value
$24.6M
Revenue (TTM)
-$52.8K
Net Income (TTM)
-$34.9M
Cash & Investments
$20.5M
Net Cash
$20.5M
Free Cash Flow (TTM)
-$71.6M
Operating CF (TTM)
-$71.5M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$20.5M
Quarterly Burn
$17.9M
Monthly Burn
$6.0M
Est. Runway
~1.1 quarters
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $2.0M | $2.3M | $192.8K | $26.1K | $57.3M | $41.0M | $21.3M | $862.1K | $17.9M | $20.5M | $20.5M | |
| Operating Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$7.8M | -$12.5M | -$23.7M | -$24.1M | -$28.5M | -$28.7M | -$71.5M | |
| Free Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$7.8M | -$12.5M | -$23.7M | -$24.6M | -$28.5M | -$28.8M | -$71.6M | |
| Capital Expenditure | $4.00 | $0.00 | -$5.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$456.8K | $0.00 | -$127.0K | -$127.1K | |
| Financing Cash Flow | $2.9M | $5.3M | $3.0M | $1.4M | $65.0M | -$3.7M | $4.0M | $4.4M | $46.0M | $31.8M | $86.8M |
R&D Spending
R&D (TTM)
$29.2M
R&D Intensity
—
R&D Growth vs Prior
+0.0%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$52.8K | |
| R&D Expense | $2.1M | $3.1M | $4.9M | $3.0M | $2.0M | $8.0M | $15.3M | $27.2M | $21.5M | $29.2M | $29.2M | |
| R&D % of Revenue | — | — | — | — | — | — | — | — | — | — | -55393.2% | |
| SG&A | $1.1M | $1.8M | $1.3M | $1.8M | $5.0M | $7.3M | $7.9M | $6.2M | $5.9M | $6.8M | $6.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$52.8K | |
| Cost of Revenue | $289.88 | $16.9K | $18.7K | $18.7K | $15.6K | $0.00 | $0.00 | $0.00 | $107.9K | $0.00 | $26.4K | |
| Gross Profit | -$289.00 | -$16.9K | -$18.7K | -$18.7K | -$15.6K | $0.00 | $0.00 | $0.00 | -$107.9K | $0.00 | -$26.4K | |
| R&D | $2.1M | $3.1M | $4.9M | $3.0M | $2.0M | $8.0M | $15.3M | $27.2M | $21.5M | $29.2M | $29.2M | |
| SG&A | $1.1M | $1.8M | $1.3M | $1.8M | $5.0M | $7.3M | $7.9M | $6.2M | $5.9M | $6.8M | $6.8M | |
| Operating Income | -$3.2M | -$5.0M | -$6.2M | -$4.8M | -$7.0M | -$15.3M | -$23.3M | -$33.3M | -$27.5M | $0.00 | -$32.4M | |
| Interest Expense | $0.00 | $20.4K | $31.3K | $36.2K | $80.1K | $979.00 | $0.00 | $0.00 | $37.4K | $0.00 | $0.00 | |
| Pretax Income | -$3.2M | -$5.4M | -$5.8M | -$4.9M | -$13.8M | -$26.8M | -$20.3M | -$4.9M | -$26.9M | -$34.9M | -$84.6M | |
| Net Income | -$3.2M | -$5.4M | -$5.8M | -$4.9M | -$13.8M | -$26.8M | -$20.3M | -$4.8M | -$26.6M | -$34.9M | -$34.9M | |
| EPS (Diluted) | -1349.43 | -1799.26 | -1497.36 | -1038.19 | -467.51 | -259.50 | -195.00 | -43.68 | -62.95 | -6.97 | -6.97 | |
| EBITDA | -$3.2M | -$5.0M | -$6.2M | -$4.8M | -$7.1M | -$26.8M | -$23.3M | -$4.8M | -$27.4M | $0.00 | -$77.6M | |
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.10 | 0.10 | 0.11 | 0.42 | 5.01 | 5.01 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.3M | $938.1K | $192.8K | $26.1K | $57.3M | $41.0M | $21.3M | $862.1K | $10.5M | $9.9M | $9.9M | |
| Short-Term Investments | $749.7K | $1.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $7.4M | $10.7M | $10.7M | |
| Total Current Assets | $2.0M | $2.4M | $206.9K | $321.0K | $57.8M | $42.3M | $26.9M | $3.7M | $20.0M | $22.0M | $22.0M | |
| Total Assets | $2.0M | $3.0M | $546.0K | $641.3K | $58.0M | $42.6M | $27.2M | $5.9M | $21.7M | $23.6M | $23.6M | |
| Total Current Liabilities | $1.1M | $1.7M | $1.4M | $4.9M | $556.8K | $941.1K | $1.8M | $7.5M | $4.0M | $8.0M | $8.0M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $26.0K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.1M | $1.7M | $1.4M | $4.9M | $30.4M | $32.2M | $30.9M | $8.6M | $4.3M | $8.0M | $8.0M | |
| Stockholders' Equity | $934.7K | $1.2M | -$845.7K | -$4.4M | $27.7M | $10.3M | -$3.8M | -$2.4M | $17.9M | $15.6M | $15.6M | |
| Retained Earnings | -$8.3M | -$12.7M | -$18.1M | -$22.3M | -$29.1M | -$60.3M | -$80.7M | -$85.4M | -$112.1M | -$146.7M | -$146.7M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$7.8M | -$12.5M | -$23.7M | -$24.1M | -$28.5M | -$28.7M | -$71.5M | |
| Capital Expenditure | $4.00 | $0.00 | -$5.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$456.8K | $0.00 | -$127.0K | -$127.1K | |
| Free Cash Flow | -$1.9M | -$5.0M | -$5.1M | -$1.6M | -$7.8M | -$12.5M | -$23.7M | -$24.6M | -$28.5M | -$28.8M | -$71.6M | |
| Investing Cash Flow | $149.9K | -$590.8K | $1.3M | $0.00 | $0.00 | $0.00 | $0.00 | -$681.8K | -$7.7M | -$3.8M | -$5.5M | |
| Financing Cash Flow | $2.9M | $5.3M | $3.0M | $1.4M | $65.0M | -$3.7M | $4.0M | $4.4M | $46.0M | $31.8M | $86.8M | |
| Issuance of Stock | $2.9M | $4.2M | $3.0M | $1.4M | $51.6M | $0.00 | $4.0M | $4.4M | $46.0M | $0.00 | -$10.9M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$10.2M | -$47.3K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $0.00 | $1.1M | $0.00 | $27.6K | -$330.4K | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M | $3.1M | $2.2M | $1.8M | $0.00 | $1.7M | $3.9M | |
| Net Change in Cash | $1.1M | -$325.8K | -$745.2K | -$166.7K | $57.2M | -$16.2M | -$19.8M | -$20.4M | $9.7M | -$641.4K | $5.9M |
Dilution Tracker
Shares outstanding grew 16531.0% over 5 years — significant dilution
Shares Outstanding
2M
5-Year Share Growth
+16531.0%
Stock Issuance (TTM)
-$10.9M
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.10 | 0.10 | 0.11 | 0.42 | 5.01 | 5.01 | |
| Change vs Prior % | — | 26.0% | 35.5% | 23.2% | 533.1% | 242.8% | 0.8% | 5.3% | 285.7% | 1084.3% | 0.0% | |
| Stock Issuance | $2.9M | $4.2M | $3.0M | $1.4M | $51.6M | $0.00 | $4.0M | $4.4M | $46.0M | $0.00 | -$10.9M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | -$10.2M | -$47.3K | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $2.0M | $3.1M | $2.2M | $1.8M | $0.00 | $1.7M | $3.9M |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | — | — | — | — | — | — | — | — | — | — | 50.0% | |
| Operating Margin % | — | — | — | — | — | — | — | — | — | — | 61419.0% | |
| Net Margin % | — | — | — | — | — | — | — | — | — | — | 66131.6% | |
| EBITDA Margin % | — | — | — | — | — | — | — | — | — | — | 147005.5% | |
| FCF Margin % | — | — | — | — | — | — | — | — | — | — | 135738.4% | |
| ROE % | -344.4% | -439.6% | 684.2% | 111.9% | -49.9% | -259.8% | 537.5% | 201.1% | -148.4% | -224.3% | -170.7% | |
| ROA % | -157.9% | -181.8% | -1059.9% | -770.5% | -23.8% | -63.0% | -74.7% | -81.6% | -122.6% | -148.0% | -147.3% | |
| ROIC % | -344.2% | -184.9% | 1383.0% | 123.4% | -12.1% | -36.7% | -91.8% | 2097.7% | -155.3% | 0.0% | -230.0% | |
| R&D / Revenue % | — | — | — | — | — | — | — | — | — | — | -55393.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 83.8% | -5742.9% | -10.9% | 0.0% | 16.9% | 100.0% | 0.0% | 0.0% | 0.0% | 100.0% | |
| Operating Income | -47.8% | -54.6% | -25.0% | 22.2% | -44.2% | -119.2% | -52.2% | -43.2% | 17.4% | 100.0% | |
| Net Income | -45.4% | -68.1% | -7.0% | 14.6% | -179.6% | -94.3% | 24.4% | 76.4% | -455.9% | -31.1% | |
| EPS (Diluted) | 0.0% | -33.3% | 16.8% | 30.7% | 55.0% | 44.5% | 24.9% | 77.6% | -44.1% | 88.9% | |
| Operating Cash Flow | -22.1% | -159.1% | -2.7% | 69.5% | -398.7% | -61.1% | -90.2% | -1.6% | -18.2% | -0.5% | |
| Free Cash Flow | -22.1% | -159.1% | -2.7% | 69.5% | -398.7% | -61.1% | -90.2% | -3.5% | -16.0% | -0.9% | |
| R&D Expense | 124.9% | 46.4% | 58.0% | -39.4% | -32.1% | 296.9% | 91.2% | 77.2% | -20.8% | 35.8% | |
| SG&A Expense | -11.3% | 69.1% | -30.4% | 43.1% | 169.4% | 46.7% | 9.2% | -22.5% | -4.1% | 15.6% | |
| Total Assets | 86.7% | 46.0% | -81.7% | 17.4% | 8951.3% | -26.6% | -36.2% | -78.4% | 269.9% | 8.5% | |
| Book Value / Share | -22.8% | 4.5% | -150.7% | -305.6% | 203.4% | -89.1% | -136.3% | 32.5% | 268.0% | -92.4% | |
| Debt | 0.0% | 0.0% | -72.9% | -22.6% | -91.5% | -100.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Diluted Shares | 17.7% | 26.0% | 35.5% | 23.2% | 533.1% | 242.8% | 0.8% | 5.3% | 285.7% | 1084.3% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B2.10
10Y Low / Med / High0.00 / 0.01 / 0.03
EV/EBITDAAt Loss
10Y Low / Med / High0.15 / 0.91 / 8.06
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$1.39
Tangible Book / Share
$1.77
Net Current Assets / Share
$7.44
Graham Net-Net
$1.44
Cash / Share
$2.36
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.01 | -0.01 | -0.03 | -0.00 | -0.01 | -0.42 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 0.00 | 0.00 | -0.01 | -0.00 | 0.00 | 0.01 | -0.04 | -0.06 | 0.01 | 0.03 | 2.10 | |
| EV/EBITDA | 0.39 | -0.11 | -0.03 | -0.06 | 8.06 | 1.53 | 0.91 | 0.15 | 0.38 | 0.00 | -0.70 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-18.85
Distress
Piotroski F-Score
1
Weak
Forward Estimates (consensus)
| Metric | FY2027 |
|---|---|
| Revenue | $10.1M |
| Net Income | $0.00 |
| EPS | $0.00 |
| # Analysts (EPS) | 0 |